Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 8/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | ENTPD5 | O75356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142960 | 1.00 | UGT2B7 (0.47) | UGT2B7CETPCA1CA2CA4 | |
| SCHEMBL4666688 | 1.00 | UGT2B7 (0.47) | UGT2B7CETPCA1CA2CA4 | |
| SCHEMBL6846565 | 0.83 | UGT2B7 (0.46) | UGT2B7CETP | |
| SCHEMBL7940649 | 0.80 | UGT2B7 (0.49) | UGT2B7CETP | |
| SCHEMBL7939563 | 0.80 | UGT2B7 (0.49) | UGT2B7CETP | |
| Propanol SCHEMBL27200262 | 0.80 | UGT2B7 (0.34) | UGT2B7 | |
| SCHEMBL29726016 | 0.80 | UGT2B7 (0.30) | UGT2B7 | |
| SCHEMBL1154981 | 0.80 | UGT2B7 (0.30) | UGT2B7 | |
| Propanol SCHEMBL1942397 | 0.79 | UGT2B7 (0.36) | UGT2B7CETPGBA1 | |
| SCHEMBL8050175 | 0.76 | CYP1A2 (0.40) | UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
| CN-103917093-B | Opsin binding ligands, compositions, and methods of use | 比卡姆药品公司 | 2017-08-11 | — | — | CN | disclosed |
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2785178-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081642-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | UGT2B7 3419/4885CETP 2899/4885CA1 3810/4885 |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, PDE6C | UGT2B7 3419/4885CETP 2899/4885CA1 3810/4885 |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | UGT2B7 3419/4885CETP 2899/4885CA1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.